Naji Yahya, Hrouch Wafa, Laadami Sara, Adali Nawal
"N.I.C.E." Research Team, "R.E.G.N.E." Research Laboratory, Faculty of Medicine and Pharmacy, Ibn Zohr University, Agadir, Morocco.
Neurology Department, Agadir University Hospital, Agadir, Morocco.
Front Neurol. 2024 Aug 23;15:1435075. doi: 10.3389/fneur.2024.1435075. eCollection 2024.
The management of epilepsy is mainly based on antiseizure medications (ASMs). More than 20 ASMs have been introduced in clinical practice, providing a multitude of prescription choices. To date, there are no published data on the trends in ASMs prescriptions in Morocco. Therefore, we conducted a survey among practicing neurologists in seven tertiary referral hospitals in Morocco to study the current ASMs prescription preferences and their modifying factors.
Our descriptive and analytical cross-sectional study was based on a survey sent between January and April 2022 to neurologists practicing in seven tertiary referral hospitals in Morocco. Information regarding the prescription of ASMs was collected using an exploitation form and analyzed using the SPSS version 13 software.
Based on questionnaire responses, our results showed that Valproic acid (96.3%) and Lamotrigine (59.8%) were the two most prescribed ASMs for generalized seizure types. For focal seizure types, Carbamazepine (98.8%) and Levetiracetam (34.1%) were the most commonly prescribed drugs, whereas for combined focal and generalized seizure types, the combination of Valproic acid and Carbamazepine (38.55%) was the most prescribed. Phenobarbital was the most commonly prescribed ASM for status epilepticus (40.2%). These prescription preferences were mainly due to seizure types, cost, health insurance coverage, years of experience, and additional epileptology training ( < 0.05).
Our results show a shift in the prescription of ASMs in Morocco. Similar to many other countries, valproic acid and carbamazepine are considered the first-line treatments for generalized and focal seizure types. Some factors remain as major challenges in enhancing epilepsy management in Morocco.
癫痫的治疗主要基于抗癫痫药物(ASMs)。临床实践中已引入20多种抗癫痫药物,提供了多种处方选择。迄今为止,摩洛哥尚无关于抗癫痫药物处方趋势的公开数据。因此,我们对摩洛哥七家三级转诊医院的神经科执业医生进行了一项调查,以研究当前抗癫痫药物的处方偏好及其影响因素。
我们的描述性和分析性横断面研究基于2022年1月至4月间发送给摩洛哥七家三级转诊医院神经科执业医生的一份调查问卷。使用一份信息采集表收集有关抗癫痫药物处方的信息,并使用SPSS 13版软件进行分析。
根据问卷回复,我们的结果显示,丙戊酸(96.3%)和拉莫三嗪(59.8%)是治疗全身性癫痫发作类型最常用的两种抗癫痫药物。对于局灶性癫痫发作类型,卡马西平(98.8%)和左乙拉西坦(34.1%)是最常用的药物,而对于局灶性和全身性癫痫发作混合型,丙戊酸和卡马西平联合用药(38.55%)是最常用的。苯巴比妥是治疗癫痫持续状态最常用的抗癫痫药物(40.2%)。这些处方偏好主要归因于癫痫发作类型、成本、医疗保险覆盖范围、经验年限以及额外的癫痫学培训(P<0.05)。
我们的结果显示摩洛哥抗癫痫药物的处方发生了变化。与许多其他国家一样,丙戊酸和卡马西平被视为全身性和局灶性癫痫发作类型的一线治疗药物。在加强摩洛哥的癫痫管理方面,一些因素仍然是重大挑战。